Join
Live feed
·
PRReleasevia Quantisnow
Tyra Biosciences Inc. logo

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

ByQuantisnow·Wall Street's wire, on your screen.
TYRA· Tyra Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TYRA (Tyra Biosciences Inc.) and more on Quantisnow.